

Cover Story
As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.
Cancer Policy


In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns

















